ANAVEX 2-73/donepezil

Drug Profile

ANAVEX 2-73/donepezil

Alternative Names: ANAVEX 2-73/DPZ; ANAVEX PLUS; Donepezil/ANAVEX 2-73

Latest Information Update: 08 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Anavex Life Sciences
  • Class Antidementias; Dimethylamines; Furans; Indans; Neuroprotectants; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; Calcium channel antagonists; Muscarinic M2 receptor antagonists; Muscarinic M3 receptor antagonists; NMDA receptor antagonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 05 Sep 2017 Anavex Life Sciences has patent protection for ANAVEX 2-73/donepezil in USA
  • 15 Mar 2017 Phase-II development is ongoing in Australia
  • 01 Jan 2017 Anavex Life Sciences completes a phase IIa trial for Alzheimer's disease in Australia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top